Mazdutide 5 mg – Product Description

The Next-Generation Dual Receptor Agonist for Metabolic Research

Mazdutide (also known as IBI-362 or LY-3305677) is a synthetic analog of oxyntomodulin—a naturally occurring peptide hormone involved in the regulation of appetite and energy balance. As a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), Mazdutide represents a sophisticated approach to metabolic research that harnesses complementary pathways for weight management and glycemic control .

Table of Contents

1. What is Mazdutide?

2. Mechanism of Action

3. Key Research Findings

4. Dosing Considerations

5. Safety Profile

6. Frequently Asked Questions (FAQs)

7. References

What is Mazdutide?

Mazdutide is a long-acting synthetic peptide with a molecular weight of 4563.06 Da and the molecular formula C₂₁₀H₃₂₂N₄₆O₆₇ . Its sequence incorporates a non-standard amino acid (Aib) and a fatty acid side chain that extends its half-life, enabling once-weekly administration in clinical research settings .

Mechanism of Action

Mazdutide functions through dual receptor agonism, each pathway contributing distinct metabolic effects :

This dual mechanism is designed to achieve greater weight loss than GLP-1 monotherapy alone. Preclinical studies have shown that Mazdutide activates oxidative phosphorylation and fatty acid degradation pathways in the liver, upregulating lipid metabolism-related genes (Ehhadh, Cyp4a14, Hadha, Fgf21, Gdf15) and promoting fatty acid oxidation .

Key Research Findings

GLORY-1 Trial (Phase 3, Obesity/Overweight)

In a 48-week randomized controlled trial of 610 Chinese adults (mean BMI 31.1), Mazdutide demonstrated clinically meaningful weight reduction :

GLORY-2 Trial (Phase 3, Moderate-Severe Obesity)

In 461 Chinese adults (mean BMI 34.3, 16% with type 2 diabetes), the 9 mg dose achieved a –16.65% weight reduction at Week 60 versus –1.50% with placebo . Notably, 85.7% achieved ≥5% weight loss, and 44.0% achieved ≥20% weight loss .

DREAMS-3 Trial (Head-to-Head vs. Semaglutide)

This ongoing phase 3 trial is directly comparing Mazdutide 6 mg against Semaglutide 1 mg in Chinese adults with type 2 diabetes and obesity (mean BMI 33.0, baseline HbA1c 8.0%) . Results are expected in early 2026.

Meta-Analysis Evidence

A systematic review of randomized controlled trials confirmed that GLP-1/glucagon dual agonists (including Mazdutide) produce significant reductions in HbA1c (MD = –0.63%) and body weight (MD = –4.16%) compared with placebo .

Dosing Considerations

Mazdutide research typically employs a titration schedule to improve gastrointestinal tolerability :

The 5 mg dose sits within the clinically studied range, supported by phase 3 data from the 4 mg and 6 mg cohorts .

Safety Profile

Mazdutide is generally well-tolerated, with the most common adverse events being gastrointestinal in nature :

Key safety observations:

• Most AEs are mild to moderate in severity and occur during the dose-escalation phase

• Treatment discontinuation rates remain low (1.5% for 4 mg, 0.5% for 6 mg, 2.9% for 9 mg) 

• Serious adverse events were comparable between Mazdutide and placebo groups 

Frequently Asked Questions (FAQs)

1. What is the primary research application for Mazdutide?

Mazdutide is studied for obesity, overweight, and type 2 diabetes (T2D) research. Its dual GLP-1/glucagon agonism makes it particularly relevant for investigating weight loss in metabolically complex populations .

2. How does Mazdutide differ from GLP-1 receptor agonists like Semaglutide?

Unlike GLP-1-only agonists, Mazdutide also activates the glucagon receptor, which contributes additional mechanisms including increased energy expenditure and enhanced hepatic fatty acid oxidation . In preclinical models, Mazdutide achieved superior weight loss (40.1% vs. 28.1%) and better liver fat reduction compared to Semaglutide monotherapy .

3. What dose is used in clinical trials?

Phase 3 trials have studied 4 mg, 6 mg, and 9 mg once-weekly doses. The 4 mg and 6 mg doses demonstrated significant efficacy with favorable tolerability profiles . Higher doses (9 mg) achieve greater weight loss but may have more gastrointestinal side effects .

4. What are the typical storage requirements?

Lyophilized powder should be stored at -80°C (stable for 2 years) or -20°C (stable for 1 year), sealed, away from moisture and light. Reconstituted solutions should be stored at -80°C (6 months) or -20°C (1 month) under nitrogen to prevent degradation .

5. What are the most common adverse events?

Gastrointestinal reactions—including nausea, vomiting, and diarrhea—are the most commonly reported adverse events. These are typically mild to moderate in severity and often occur during dose escalation .

6. Does Mazdutide have cardiovascular benefits?

GLORY-1 reported beneficial effects on all prespecified cardiometabolic measures, including serum triglycerides, total cholesterol, and LDL-C . However, weight loss with Mazdutide primarily comes from total fat mass reduction, though lean mass loss has been observed and warrants further investigation .

7. Is Mazdutide approved for therapeutic use?

No. Mazdutide is currently an investigational research peptide and is not FDA-approved for human therapeutic use. It is provided for research purposes only .

References

1. TargetMol. Mazdutide (IBI-362; LY-3305677) – Product Information 

2. Ji L, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392:2215-2225 

3. Luo Y, et al. Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: DREAMS-3 trial. Diabetes Res Clin Pract. 2025 

4. WO2025073288A1 – Patent Application: Mazdutide Dosing Regimens 

5. MedChemExpress. Mazdutide HY-P3375 – Product Specifications 

6. Wu Q, et al. 777-P: Mazdutide Outbalanced Semaglutide in Improving Liver Fat Accumulation. Diabetes. 2025;74(Supplement_1) 

7. Padilla S. Mazdutide cuts weight in adults with obesity, T2D. MIMS Malaysia. 2026 

8. Selleckchem. Mazdutide (IBI362, LY330567) – Product Information 

9. Deng B, et al. Safety and efficacy of GLP-1 and glucagon receptor dual agonist for T2D and obesity. Endocrine. 2024 

10. JAMA. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: GLORY-2 Trial. JAMA. 2026